Join the NLA to solve the mystery of genetic dyslipidemias. Our panel will explore the mechanisms and manifestations of Familial Hypercholesterolemia (Heterozygous and Homozygous), Sitosterolemia, and Lysosomal Acid Lipase Deficiency. After reviewing patient profiles, you will make your diagnosis and receive real-time critiques from our panel. We will explore expert recommendations for clinical and genetic diagnosis confirmations, management strategies, and methods to maximize patient engagement throughout the life cycle.
Internet Enduring Activity
FEE FOR PARTICIPATION
RELEASE DATE: March 16, 2020
EXPIRATION DATE: March 16, 2021
This activity is designed to meet the needs of lipidologist, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, and advance practice registered nurses with an interest in lipid management.
At the Conclusion of this activity, participants should be able to:
- This activity is designed to meet the needs of lipidologist, internists, endocrinologists, physician assistants, pharmacists, registered nurses, nurse practitioners, and advance practice registered nurses with an interest in lipid management.
- Counsel patients with complex lipid disorders on treatment and/or management plans.
CRITERIA FOR SUCCESS
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 100% on the post-test. The deadline to claim credit is March 16, 2021.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
This activity is supported by educational funding provided by Alexion.
CME credit provided by the National Lipid Association
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this enduring internet activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
Pharmacist Accreditation Statement
Universal Activity Number – JA0007192-0000-20-009-H01-P (Application)
This Activity has been approved for 1.00 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
The maximum number of hours awarded for this CE activity is 1.0 contact hours.
Daniel E. Soffer, MD, FNLA
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Director of Pediatric Cardiology
Ascension St. John Children's Hospital
Clinical Assistant Professor of Pediatrics
Wayne State University School of Medicine
Past- President, National Lipid Association
Clinical Assistant Professor of Medicine
Director, Bellevue Hospital Lipid Clinic
New York, NY
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME. .
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
|Premchand Anne, MD, MPH, MBA||N/A||Nothing to disclose|
|Daniel E. Soffer, MD, FNLA||
Akcea, Amgen, AstraZeneca, Esperion, Ionis Pharmaceuticals, Kowa, Novartis, Sanofi, Regeneron, Regenex
|James A. Underberg, MD, MS, FNLA||
Amgen, Sanofi, Regeneron, Ambry, Alexion, Akcea, Amarin
Amgen, Amarin, Aegerion, Alexion, Akcea, Sanofi, Regeneron
|NLA||N/A||NLA staff has nothing to disclose.|
|B Bottenberg, DO, FNLA||N/A||Nothing to disclose.|
|Casey Elkins, DNP, CLS, FNLA||Speaker||Regeneron/ Sanofi|
This page was last updated: Mar 16, 2020